The correlation between plasma aprepitant concentration and antiemetic effect in Japanese gastric or esophageal cancer patients
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605490988 | ||
| 003 | CHVBK | ||
| 005 | 20210128100507.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150601xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10147-014-0747-6 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10147-014-0747-6 | ||
| 245 | 0 | 4 | |a The correlation between plasma aprepitant concentration and antiemetic effect in Japanese gastric or esophageal cancer patients |h [Elektronische Daten] |c [Kosuke Nishizawa, Hideaki Shimada, Masaaki Ito, Yoko Oshima, Satoshi Yajima, Yoshinori Kikuchi, Yasukiyo Sumino, Hironori Kaneko, Kenji Nishizawa, Masahiko Obayashi] |
| 520 | 3 | |a Background: Chemotherapy-induced nausea and vomiting (CINV) are significant problems in cancer patients, but a correlation between plasma aprepitant concentration and antiemetic effect has not been reported. This study aimed to characterize the correlation between plasma aprepitant concentration and clinical antiemetic effect in a limited group of Japanese gastric or esophageal cancer patients. Methods: Thirty-three Japanese cancer patients receiving cisplatin-based chemotherapy for the first time following oral aprepitant (125mg on day 1 and 80mg on days 2 and 3) were enrolled. The plasma aprepitant concentrations 48h after the first administration were determined using liquid chromatography-mass spectrometry. Patients were allocated to the high-concentration group (plasma aprepitant concentration was >331.1ng/ml) or the low-concentration group (plasma aprepitant concentration was ≤331.1ng/ml) to investigate the relationship between plasma aprepitant concentration and antiemetic effects. Results: No significant differences were found between the two groups in terms of percentage of CINV prevention. Of 13 patients who experienced CINV [MASCC Antiemesis Tool (MAT) score >3], those in the high-concentration group showed a significant improvement in CINV following aprepitant administration (days 1-3). Conclusion: The present study suggests that the antiemetic effect of aprepitant is associated with plasma aprepitant concentration. A plasma aprepitant concentration of 331.1ng/ml may be a valid threshold for identifying its optimal antiemetic effects in Japanese gastric or esophageal cancer patients. | |
| 540 | |a Japan Society of Clinical Oncology, 2014 | ||
| 690 | 7 | |a Chemotherapy |2 nationallicence | |
| 690 | 7 | |a Nausea |2 nationallicence | |
| 690 | 7 | |a Vomiting |2 nationallicence | |
| 690 | 7 | |a Aprepitant |2 nationallicence | |
| 700 | 1 | |a Nishizawa |D Kosuke |u Department of Pharmacy, Toho University Omori Medical Center, 6-11-1, Omori-nishi, Ota-ku, 143-8541, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Shimada |D Hideaki |u Department of Surgery, School of Medicine, Toho University, 6-11-1, Omori-nishi, Ota-ku, 143-8541, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Ito |D Masaaki |u Department of Surgery, School of Medicine, Toho University, 6-11-1, Omori-nishi, Ota-ku, 143-8541, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Oshima |D Yoko |u Department of Surgery, School of Medicine, Toho University, 6-11-1, Omori-nishi, Ota-ku, 143-8541, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Yajima |D Satoshi |u Department of Surgery, School of Medicine, Toho University, 6-11-1, Omori-nishi, Ota-ku, 143-8541, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Kikuchi |D Yoshinori |u Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), School of Medicine, Faculty of Medicine, Toho University, 5-21-16, Omori-nishi, Ota-ku, 143-8540, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Sumino |D Yasukiyo |u Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), School of Medicine, Faculty of Medicine, Toho University, 5-21-16, Omori-nishi, Ota-ku, 143-8540, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Kaneko |D Hironori |u Department of Surgery, School of Medicine, Toho University, 6-11-1, Omori-nishi, Ota-ku, 143-8541, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Nishizawa |D Kenji |u Department of Pharmacy, Toho University Omori Medical Center, 6-11-1, Omori-nishi, Ota-ku, 143-8541, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Obayashi |D Masahiko |u Department of Clinical Pharmaceutics, School of Pharmaceutical Sciences, Toho University, 2-2-1, Miyama, 274-8510, Funabashi, Chiba, Japan |4 aut | |
| 773 | 0 | |t International Journal of Clinical Oncology |d Springer Japan |g 20/3(2015-06-01), 538-542 |x 1341-9625 |q 20:3<538 |1 2015 |2 20 |o 10147 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10147-014-0747-6 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10147-014-0747-6 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Nishizawa |D Kosuke |u Department of Pharmacy, Toho University Omori Medical Center, 6-11-1, Omori-nishi, Ota-ku, 143-8541, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Shimada |D Hideaki |u Department of Surgery, School of Medicine, Toho University, 6-11-1, Omori-nishi, Ota-ku, 143-8541, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Ito |D Masaaki |u Department of Surgery, School of Medicine, Toho University, 6-11-1, Omori-nishi, Ota-ku, 143-8541, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Oshima |D Yoko |u Department of Surgery, School of Medicine, Toho University, 6-11-1, Omori-nishi, Ota-ku, 143-8541, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Yajima |D Satoshi |u Department of Surgery, School of Medicine, Toho University, 6-11-1, Omori-nishi, Ota-ku, 143-8541, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kikuchi |D Yoshinori |u Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), School of Medicine, Faculty of Medicine, Toho University, 5-21-16, Omori-nishi, Ota-ku, 143-8540, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Sumino |D Yasukiyo |u Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), School of Medicine, Faculty of Medicine, Toho University, 5-21-16, Omori-nishi, Ota-ku, 143-8540, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kaneko |D Hironori |u Department of Surgery, School of Medicine, Toho University, 6-11-1, Omori-nishi, Ota-ku, 143-8541, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Nishizawa |D Kenji |u Department of Pharmacy, Toho University Omori Medical Center, 6-11-1, Omori-nishi, Ota-ku, 143-8541, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Obayashi |D Masahiko |u Department of Clinical Pharmaceutics, School of Pharmaceutical Sciences, Toho University, 2-2-1, Miyama, 274-8510, Funabashi, Chiba, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t International Journal of Clinical Oncology |d Springer Japan |g 20/3(2015-06-01), 538-542 |x 1341-9625 |q 20:3<538 |1 2015 |2 20 |o 10147 | ||